查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1918113

肝素市場－2026-2031年預測

Heparin Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 153 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計肝素市場將以 5.0% 的複合年成長率成長，從 2025 年的 65.98 億美元成長到 2031 年的 88.4 億美元。

由於肝素在預防和治療血栓性疾病方面發揮著至關重要的抗凝血作用，因此肝素市場是製藥業的重要組成部分。肝素的主要功能是抑制血液凝固，使其在外科手術、心血管疾病治療和腎臟透析中不可或缺。市場成長軌跡受到人口趨勢、特定疾病的流行以及該藥物廣泛的治療效用等多種因素的影響，但同時也受到重大安全隱患的限制。

市場擴張的主要促進因素是全球心血管疾病負擔日益惡化。強效抗凝血​​治療對於預防中風和其他血栓栓塞併發症至關重要，例如心房顫動和心肌梗塞後併發症病例的不斷增加。這些疾病發生率的上升與對抗凝劑需求的成長直接相關，而肝素仍然是治療的基石，尤其是在急性期和手術全期。

全球人口老化趨勢也在推動市場需求。老年人特別容易患心血管疾病，並且更頻繁地接受外科手術，例如整形外科和心血管手術，而肝素在這些手術中通常用於血栓預防。這種人口趨勢導致需要抗凝血治療的患者群體持續成長，從而確保了肝素使用的穩定基礎。

肝素在各種臨床場景中的廣泛應用極大地支持了其市場地位。它在多個領域已被廣泛應用：例如，作為手術（如心臟直視手術和搭橋手術）後的預防和治療藥物，作為腎透析迴路中的抗凝血劑，以及用於治療瀰漫性血管內凝血等嚴重疾病。這種臨床上的多功能性，以及包括低分子量肝素（如依諾肝素）在內的多種製劑形式，確保了其在醫院醫學、外科和腎臟病學領域持續發揮重要作用。

儘管市場需求強勁，但肝素市場仍面臨許多限制因素，主要與藥物安全性相關。肝素治療有嚴重副作用的風險，尤其是肝素誘發的血小板減少性疾病（HIT），這種疾病反而可能導致危及生命的血栓症。此外，肝素本身有出血風險，因此需要由經驗豐富的醫護人員進行嚴格的劑量管理和監測。這些安全隱患，加上嚴格的監管制度，可能會限制肝素的普及，尤其是在醫療資源和專業知識有限的醫療系統中，從而限制市場成長。

從區域來看，北美預計將成為領先的市場。這一優勢歸功於該地區心血管疾病的高發病率、能夠管理複雜抗凝血療法的先進醫療基礎設施，以及支持基本藥物普及的高額醫療支出。龐大的老年人口和健全的臨床研究與創新體系進一步鞏固了該地區在全球肝素市場的主導地位。

競爭格局包括賽諾菲、利奧製藥和阿斯彭控股等成熟的跨國製藥公司。這些公司提供種類繁多的肝素類產品，包括品牌低分子量肝素和原料藥。在面臨安全管理挑戰和臨床指南不斷更新的市場環境下，它們持續佔有一席之地，凸顯了肝素作為醫療保健關鍵工具的重要性。因此，市場穩定性源自於肝素在滿足基本和日益成長的臨床需求方面不可替代的作用。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2021-2025 年）和預測資料（2026-2031 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

5. 全球肝素市場（依產品類型分類）

  • 介紹
  • 低分子量肝素
  • 未分級肝素

6. 全球肝素市場依給藥途徑分類

  • 介紹
  • 靜脈輸液
  • 皮下注射

7. 全球肝素市場依應用領域分類

  • 介紹
  • 心房顫動
  • 靜脈血栓症
  • 輸血
  • 其他

8. 全球肝素市場（依最終用戶分類）

  • 介紹
  • 醫院
  • 門診手術中心
  • 其他

9. 全球肝素市場（依地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第10章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第11章 公司簡介

  • Pfizer, Inc.
  • LEO Pharma A/S
  • Sanofi
  • Dr. Reddy's Laboratories Ltd.
  • B. Braun Medical Inc.
  • Fresenius SE & Co. KGaA
  • Sandoz Group AZ
  • Shenzhen Hepalink Pharmaceutical
  • Teva Pharmaceutical Industries Ltd.
  • Amphastar Pharmaceuticals Inc.
  • Opocrin SpA

第12章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 分析方法
  • 簡稱
簡介目錄
Product Code: KSI061615585

The heparin market, with a 5.0% CAGR, is projected to increase from USD 6.598 billion in 2025 to USD 8.84 billion in 2031.

The heparin market is a critical segment within the pharmaceutical industry, driven by the essential role of this anticoagulant in preventing and treating thrombotic conditions. Heparin's primary function is to inhibit blood clotting, making it indispensable in surgical procedures, the management of cardiovascular diseases, and renal dialysis. The market's growth trajectory is shaped by a combination of demographic trends, the prevalence of specific disease states, and the drug's broad therapeutic utility, though it is moderated by significant safety considerations.

A principal driver of market expansion is the escalating global burden of cardiovascular diseases. Conditions such as atrial fibrillation and the high volume of post-myocardial infarction cases necessitate robust anticoagulation therapy to prevent stroke and other thromboembolic complications. The increasing incidence of these disorders directly correlates with a rising demand for anticoagulant medications, with heparin remaining a cornerstone therapy, particularly in acute and perioperative settings.

The demographic shift towards an aging global population further amplifies market demand. Older adults are disproportionately affected by cardiovascular conditions and are more frequently candidates for surgical interventions, including orthopedic and cardiovascular surgeries, where heparin is routinely used for thromboprophylaxis. This demographic trend ensures a growing and sustained patient population requiring anticoagulation management, thereby securing a stable foundation for heparin utilization.

Heparin's extensive application portfolio across various clinical scenarios significantly contributes to its market presence. Its use is well-established in multiple domains: as a prophylactic and therapeutic agent post-surgery (e.g., open-heart and bypass surgery), in renal dialysis circuits to prevent clotting, and in the treatment of serious conditions like disseminated intravascular coagulation. This clinical versatility, supported by various formulations such as low molecular weight heparins (e.g., enoxaparin), ensures its continued relevance across hospital medicine, surgery, and nephrology.

Despite strong demand drivers, the market faces notable restraints primarily related to drug safety. Heparin therapy carries the risk of serious adverse effects, most notably heparin-induced thrombocytopenia (HIT), a condition that can paradoxically lead to life-threatening thrombosis. Furthermore, the inherent risk of major bleeding requires careful dose management and monitoring by skilled healthcare professionals. These safety concerns, coupled with stringent regulatory oversight governing its use, can limit its application, particularly in healthcare systems with limited resources or expertise, thereby acting as a moderating factor on market growth.

Geographically, North America is anticipated to be a significant marketplace. This prominence is attributed to the region's high prevalence of cardiovascular diseases, a technologically advanced healthcare infrastructure capable of managing complex anticoagulation regimens, and substantial healthcare expenditure that supports the adoption of essential medicines. The presence of a large aging population and a robust framework for clinical research and innovation further consolidates the region's leading position in the global heparin market.

The competitive landscape includes established multinational pharmaceutical companies such as Sanofi, LEO Pharma, and Aspen Holdings. These players offer a range of heparin-based products, including branded low molecular weight heparins and active pharmaceutical ingredients. Their sustained presence underscores the continued importance of heparin as a critical tool in the medical arsenal, even as the market navigates the challenges of safety management and evolving clinical guidelines. The market's stability is thus derived from its irreplaceable role in addressing fundamental and growing clinical needs.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Heparin Market Segmentation:

  • By Product Type
  • Low-Molecular Weight Heparin
  • Unfractionated Heparin
  • By Route of Administration
  • Intravenous Infusion
  • Subcutaneous Injection
  • By Application
  • Atrial Fibrillation
  • Venous Thrombosis
  • Blood Transfusion
  • Others
  • By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL HEPARIN MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Low-Molecular Weight Heparin
  • 5.3. Unfractioned Heparin

6. GLOBAL HEPARIN MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Intravenous Infusion
  • 6.3. Subcutaneous Injection

7. GLOBAL HEPARIN MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Atrial Fibrillation
  • 7.3. Venous Thrombosis
  • 7.4. Blood Transfusion
  • 7.5. Others

8. GLOBAL HEPARIN MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Others

9. GLOBAL HEPARIN MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Italy
    • 9.4.6. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Pfizer, Inc.
  • 11.2. LEO Pharma A/S
  • 11.3. Sanofi
  • 11.4. Dr. Reddy's Laboratories Ltd.
  • 11.5. B. Braun Medical Inc.
  • 11.6. Fresenius SE & Co. KGaA
  • 11.7. Sandoz Group AZ
  • 11.8. Shenzhen Hepalink Pharmaceutical
  • 11.9. Teva Pharmaceutical Industries Ltd.
  • 11.10. Amphastar Pharmaceuticals Inc.
  • 11.11. Opocrin S.p.A

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations